Top Page
4DMedical Ltd
(Sydney:4DX)
4DMedical Ltd (4DX) vs. iShares MSCI Australia ETF (EWA)
4DMedical Ltd Business Overview & Revenue Model
4DMedical Ltd Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 4.37M | 5.85M | 3.75M | 718.58K | 1.05M | 216.98K |
| Gross Profit | 4.05M | 5.39M | 3.52M | 684.43K | 280.62K | 125.13K |
| EBITDA | -34.14M | -45.82M | -31.86M | -33.74M | -35.25M | -18.04M |
| Net Income | -24.62M | -30.07M | -35.98M | -31.46M | -24.59M | -21.42M |
Balance Sheet | ||||||
| Total Assets | 94.81M | 94.81M | 120.02M | 92.92M | 74.31M | 92.64M |
| Cash, Cash Equivalents and Short-Term Investments | 6.88M | 6.88M | 30.61M | 69.58M | 51.11M | 80.88M |
| Total Debt | 4.31M | 4.31M | 5.12M | 5.14M | 6.24M | 1.69M |
| Total Liabilities | 30.58M | 30.58M | 49.09M | 21.46M | 14.80M | 9.28M |
| Stockholders Equity | 64.24M | 64.24M | 70.93M | 71.46M | 59.51M | 83.36M |
Cash Flow | ||||||
| Free Cash Flow | -24.37M | -34.56M | -31.17M | -23.38M | -28.35M | -15.25M |
| Operating Cash Flow | -24.31M | -34.48M | -30.87M | -22.65M | -25.27M | -14.52M |
| Investing Cash Flow | -1.62M | -1.62M | -40.04M | -1.61M | -3.50M | -580.45K |
| Financing Cash Flow | 12.37M | 12.37M | 31.94M | 42.73M | -995.47K | 87.55M |
4DMedical Ltd Technical Analysis
4DMedical Ltd Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| ― | AU$255.32M | ― | -4.06% | ― | 20.36% | 64.81% | |
| ― | AU$73.46M | ― | -128.19% | ― | -14.25% | -22.83% | |
| ― | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
| ― | AU$897.90M | ― | -44.49% | ― | 55.91% | 22.60% | |
| ― | $77.37M | ― | -74.00% | ― | 23.31% | -17.35% | |
| ― | AU$170.03M | -16.13 | -70.55% | ― | ― | -257.32% | |
| ― | AU$81.13M | ― | -31.98% | ― | 34.20% | -23.90% |
4DMedical Ltd Corporate Events
4DMedical Limited announced the successful passage of all resolutions at its Annual General Meeting, reflecting strong shareholder support. The resolutions included re-elections of directors and the issuance of options and restricted stock units to key personnel, indicating a strategic focus on leadership stability and incentivization. This outcome supports 4DMedical’s ongoing efforts to enhance its market position and operational capabilities in the medical imaging industry.
The most recent analyst rating on (AU:4DX) stock is a Hold with a A$2.00 price target. To see the full list of analyst forecasts on 4DMedical Ltd stock, see the AU:4DX Stock Forecast page.
4DMedical Limited has achieved a major milestone with the FDA clearance of its CT:VQ™ technology, the first non-contrast, CT-based ventilation-perfusion imaging solution. This approval, coupled with immediate reimbursement confirmation from CMS, positions CT:VQ™ to potentially replace traditional nuclear VQ imaging, tapping into a billion-dollar market. The company has rapidly expanded its commercial footprint, with Stanford University adopting the technology and partnerships with AstraZeneca in Brazil and key contracts in Australia. These developments, alongside strong financial performance and strategic partnerships, underscore 4DMedical’s growing influence in the respiratory imaging sector.
The most recent analyst rating on (AU:4DX) stock is a Hold with a A$2.00 price target. To see the full list of analyst forecasts on 4DMedical Ltd stock, see the AU:4DX Stock Forecast page.
4DMedical Limited presented its achievements and future plans at the 2025 Annual General Meeting, highlighting a 95% increase in SaaS revenue and the successful launch of the CT:VQ solution, which received FDA clearance and its first commercial contract. The company reported a total income of $16.5 million for FY25 and maintained a strong cash balance of $33.5 million. With strategic investments in U.S. market initiatives and global industry conferences, 4DMedical is poised to capitalize on a large global market opportunity, particularly with its CT:VQ solution, which aims to improve patient care by reducing costs and enhancing access.
The most recent analyst rating on (AU:4DX) stock is a Hold with a A$2.00 price target. To see the full list of analyst forecasts on 4DMedical Ltd stock, see the AU:4DX Stock Forecast page.
4DMedical Limited announced the withdrawal of Resolution 8 from its upcoming Annual General Meeting agenda due to the ASX not granting a waiver from Listing Rule 7.5.4. This resolution involved ratifying a prior agreement to issue shares to Pro Medicus Limited. The withdrawal will not affect the validity of proxy forms already submitted for other resolutions at the AGM. This decision reflects the company’s adherence to regulatory requirements and may impact its strategic financial arrangements.
The most recent analyst rating on (AU:4DX) stock is a Hold with a A$2.00 price target. To see the full list of analyst forecasts on 4DMedical Ltd stock, see the AU:4DX Stock Forecast page.
4DMedical Ltd announced the quotation of 492,109 fully paid ordinary securities on the Australian Securities Exchange (ASX) under the code 4DX. This move reflects the company’s ongoing efforts to enhance its financial flexibility and support its growth strategy, potentially impacting its market position and offering new opportunities for stakeholders.
The most recent analyst rating on (AU:4DX) stock is a Hold with a A$2.00 price target. To see the full list of analyst forecasts on 4DMedical Ltd stock, see the AU:4DX Stock Forecast page.
4DMedical Limited has announced the commercial rollout of its CT:VQ™ technology at Stanford University, marking the first U.S. Academic Medical Centre to adopt the FDA-cleared technology. This move is part of a broader strategy to establish CT:VQ™ as a new standard of care in pulmonary imaging across leading U.S. institutions. Additionally, 4DMedical, in partnership with AstraZeneca, is expanding its Lung Health Screening Program in Brazil to five more hospitals, significantly increasing the program’s reach and impact. These developments are expected to accelerate clinical adoption and generate real-world evidence, positioning 4DMedical as a leader in respiratory imaging technology.
The most recent analyst rating on (AU:4DX) stock is a Hold with a A$2.00 price target. To see the full list of analyst forecasts on 4DMedical Ltd stock, see the AU:4DX Stock Forecast page.
4DMedical Ltd has announced the quotation of 377,371 fully paid ordinary securities on the Australian Securities Exchange (ASX). This move is part of the company’s ongoing efforts to leverage financial instruments for growth and expansion, potentially impacting its market position and offering new opportunities for stakeholders.
The most recent analyst rating on (AU:4DX) stock is a Hold with a A$2.00 price target. To see the full list of analyst forecasts on 4DMedical Ltd stock, see the AU:4DX Stock Forecast page.
4DMedical Limited has issued 1,356,416 fully paid ordinary shares following the exercise of options under its Long Term Incentive Plan. This move, disclosed without the need for a prospectus under the Corporations Act, indicates the company’s compliance with relevant regulations and supports its strategic growth initiatives.
The most recent analyst rating on (AU:4DX) stock is a Hold with a A$2.00 price target. To see the full list of analyst forecasts on 4DMedical Ltd stock, see the AU:4DX Stock Forecast page.
4DMedical Ltd has announced the quotation of 1,356,416 fully paid ordinary securities on the Australian Securities Exchange (ASX). This move, resulting from the exercise of options or conversion of other securities, is expected to bolster the company’s financial standing and potentially enhance its market position.
The most recent analyst rating on (AU:4DX) stock is a Hold with a A$2.00 price target. To see the full list of analyst forecasts on 4DMedical Ltd stock, see the AU:4DX Stock Forecast page.
4DMedical Ltd has announced the quotation of 2,404,728 fully paid ordinary securities on the Australian Securities Exchange (ASX), effective from October 9, 2025. This move is part of the company’s strategic efforts to enhance its market presence and provide liquidity to its stakeholders, potentially strengthening its position in the medical technology sector.
The most recent analyst rating on (AU:4DX) stock is a Hold with a A$2.00 price target. To see the full list of analyst forecasts on 4DMedical Ltd stock, see the AU:4DX Stock Forecast page.
4DMedical Ltd announced the issuance of unquoted securities, including 679,085 performance rights and 2,711,738 options, as part of an employee incentive scheme. This move is likely to impact the company’s operational strategy by aligning employee interests with company performance, potentially enhancing its market position and stakeholder value.
The most recent analyst rating on (AU:4DX) stock is a Hold with a A$2.00 price target. To see the full list of analyst forecasts on 4DMedical Ltd stock, see the AU:4DX Stock Forecast page.
4DMedical Limited has successfully raised $22.6 million through the exercise of deep in-the-money options, significantly boosting its cash reserves to $45.5 million. This financial influx, alongside strategic investments and tax incentives, will support the company’s strategic priorities, including the commercialization of its CT:VQ™ solution and expansion into the U.S. healthcare market. The company is also poised for further capital inflows with additional options set to expire in December 2025, potentially adding $30.2 million to its balance sheet. These developments underscore 4DMedical’s commitment to advancing its market position and enhancing its product offerings in the respiratory imaging industry.
The most recent analyst rating on (AU:4DX) stock is a Buy with a A$2.50 price target. To see the full list of analyst forecasts on 4DMedical Ltd stock, see the AU:4DX Stock Forecast page.
4DMedical Ltd has announced the quotation of 365,338 fully paid ordinary securities on the Australian Securities Exchange (ASX) as of October 2, 2025. This move is part of the company’s strategy to enhance its financial flexibility and support its growth initiatives, potentially impacting its market position and providing value to its stakeholders.
The most recent analyst rating on (AU:4DX) stock is a Buy with a A$2.50 price target. To see the full list of analyst forecasts on 4DMedical Ltd stock, see the AU:4DX Stock Forecast page.
4DMedical Ltd has announced the issuance of piggyback options following the exercise of previously listed options, with a total of 1,065,402 securities set to be quoted. This move is part of the company’s strategic efforts to strengthen its market position and potentially increase its capital base, which could have significant implications for its stakeholders and future growth opportunities.
The most recent analyst rating on (AU:4DX) stock is a Buy with a A$2.50 price target. To see the full list of analyst forecasts on 4DMedical Ltd stock, see the AU:4DX Stock Forecast page.
4DMedical Ltd has announced the application for the quotation of new securities on the ASX, following the conversion of options or other convertible securities. This move is part of the company’s ongoing efforts to strengthen its financial position and expand its market presence, potentially impacting its operational capabilities and stakeholder interests positively.
The most recent analyst rating on (AU:4DX) stock is a Buy with a A$2.50 price target. To see the full list of analyst forecasts on 4DMedical Ltd stock, see the AU:4DX Stock Forecast page.
4DMedical Ltd has announced the quotation of new securities on the Australian Securities Exchange (ASX), specifically piggyback options issued upon the exercise of previously listed options. This move, involving over 3 million securities, is part of the company’s strategic financial operations to enhance its market positioning and provide value to its stakeholders.
The most recent analyst rating on (AU:4DX) stock is a Buy with a A$2.50 price target. To see the full list of analyst forecasts on 4DMedical Ltd stock, see the AU:4DX Stock Forecast page.
4DMedical Ltd has announced a new application for the quotation of securities on the Australian Securities Exchange (ASX). The securities, which have been issued as a result of options being exercised or convertible securities being converted, are part of the company’s strategic financial maneuvers. This move is expected to enhance the company’s market presence and provide additional capital to support its ongoing operations and growth initiatives.
The most recent analyst rating on (AU:4DX) stock is a Buy with a A$2.50 price target. To see the full list of analyst forecasts on 4DMedical Ltd stock, see the AU:4DX Stock Forecast page.
4DMedical Limited has announced its Annual General Meeting scheduled for 30 October 2025, where shareholders will review the company’s FY25 performance and vote on various business items, including the re-election of directors and the issuance of securities. This meeting is a significant event for stakeholders as it will provide insights into the company’s strategic direction and financial health, potentially impacting its market positioning and investor confidence.
The most recent analyst rating on (AU:4DX) stock is a Buy with a A$2.50 price target. To see the full list of analyst forecasts on 4DMedical Ltd stock, see the AU:4DX Stock Forecast page.
4DMedical Limited has released its 2025 Corporate Governance Statement, detailing its adherence to the ASX Corporate Governance Council’s Principles and Recommendations. The company emphasizes its commitment to transparency and accountability by outlining its governance framework, which includes policies on anti-bribery, risk management, and diversity. This announcement reinforces 4DMedical’s dedication to maintaining high standards of corporate governance, which is crucial for its stakeholders, including shareholders, employees, and the community.
The most recent analyst rating on (AU:4DX) stock is a Buy with a A$1.05 price target. To see the full list of analyst forecasts on 4DMedical Ltd stock, see the AU:4DX Stock Forecast page.
4DMedical’s Annual Report for 2025 highlights its continued efforts in revolutionizing lung imaging technology, particularly through its CT:VQ™ product. The report outlines strategic growth, commercial partnerships, and clinical research initiatives, positioning the company as a leader in the cardiopulmonary imaging sector and indicating a strong outlook for FY26.
The most recent analyst rating on (AU:4DX) stock is a Buy with a A$1.05 price target. To see the full list of analyst forecasts on 4DMedical Ltd stock, see the AU:4DX Stock Forecast page.
4DMedical Ltd has announced the quotation of 56,250 fully paid ordinary securities on the Australian Securities Exchange (ASX) under the code 4DX, following the exercise of options or conversion of other convertible securities. This move is expected to enhance the company’s liquidity and potentially attract more investors, reinforcing its position in the medical imaging sector.
The most recent analyst rating on (AU:4DX) stock is a Buy with a A$1.05 price target. To see the full list of analyst forecasts on 4DMedical Ltd stock, see the AU:4DX Stock Forecast page.
4DMedical Ltd has announced the quotation of new securities on the ASX, specifically piggyback options issued upon the exercise of previously listed options. This development involves the issuance of 2,872,980 options set to expire on September 1, 2027. The move is part of the company’s strategic financial operations, potentially impacting its market presence and offering stakeholders an opportunity for investment growth.
The most recent analyst rating on (AU:4DX) stock is a Buy with a A$1.05 price target. To see the full list of analyst forecasts on 4DMedical Ltd stock, see the AU:4DX Stock Forecast page.
4DMedical Ltd has announced the quotation of 2,872,980 fully paid ordinary securities on the Australian Securities Exchange (ASX), effective September 25, 2025. This move is part of the company’s strategic efforts to enhance its market presence and provide additional value to its stakeholders by expanding its financial resources.
The most recent analyst rating on (AU:4DX) stock is a Buy with a A$1.05 price target. To see the full list of analyst forecasts on 4DMedical Ltd stock, see the AU:4DX Stock Forecast page.
4DMedical Ltd has announced the issuance of new securities, specifically piggyback options, following the exercise of previously listed options. This move, involving the quotation of over 3.5 million securities, is part of the company’s strategic financial maneuvers to enhance its market position and operational capabilities.
The most recent analyst rating on (AU:4DX) stock is a Buy with a A$1.05 price target. To see the full list of analyst forecasts on 4DMedical Ltd stock, see the AU:4DX Stock Forecast page.
4DMedical Ltd announced the issuance of 3,580,890 new fully paid ordinary shares, which will be quoted on the Australian Securities Exchange (ASX) under the code 4DX. This move is part of the company’s strategy to strengthen its financial position and support its growth initiatives in the medical imaging sector.
The most recent analyst rating on (AU:4DX) stock is a Buy with a A$1.05 price target. To see the full list of analyst forecasts on 4DMedical Ltd stock, see the AU:4DX Stock Forecast page.
4DMedical Ltd has announced the quotation of new securities, specifically piggyback options, on the Australian Securities Exchange (ASX). The issuance of these options, expiring on September 1, 2027, reflects the company’s ongoing efforts to strengthen its financial position and enhance shareholder value. This strategic move may impact the company’s market presence and offer potential benefits to stakeholders by providing additional investment opportunities.
The most recent analyst rating on (AU:4DX) stock is a Buy with a A$1.05 price target. To see the full list of analyst forecasts on 4DMedical Ltd stock, see the AU:4DX Stock Forecast page.
4DMedical Ltd has announced the quotation of 2,913,928 fully paid ordinary securities on the Australian Securities Exchange (ASX) under the code 4DX, effective from September 18, 2025. This move is part of the company’s strategy to leverage convertible securities, potentially enhancing its market presence and providing additional capital to support its operations and growth initiatives.
The most recent analyst rating on (AU:4DX) stock is a Buy with a A$1.05 price target. To see the full list of analyst forecasts on 4DMedical Ltd stock, see the AU:4DX Stock Forecast page.
4DMedical Ltd has announced the quotation of new securities on the Australian Securities Exchange (ASX), specifically piggyback options issued upon the exercise of previously listed options. This move is part of the company’s strategic financial maneuvers to bolster its market position and potentially increase its capital base, which could have significant implications for its operational capabilities and stakeholder interests.
The most recent analyst rating on (AU:4DX) stock is a Buy with a A$1.05 price target. To see the full list of analyst forecasts on 4DMedical Ltd stock, see the AU:4DX Stock Forecast page.
4DMedical Ltd has announced the quotation of 4,166,698 ordinary fully paid securities on the Australian Securities Exchange (ASX) under the code 4DX. This move is part of the company’s strategic efforts to leverage convertible securities, potentially enhancing its financial flexibility and market presence.
The most recent analyst rating on (AU:4DX) stock is a Buy with a A$1.05 price target. To see the full list of analyst forecasts on 4DMedical Ltd stock, see the AU:4DX Stock Forecast page.
4DMedical Limited is hosting an exclusive webinar featuring Dr. Kyle Hogarth, a renowned pulmonologist, to discuss the clinical applications and benefits of 4DMedical’s respiratory imaging technology. This session aims to provide shareholders with insights into the company’s innovative products and their impact on lung care, highlighting the advantages over traditional diagnostic methods and the future of respiratory imaging.
The most recent analyst rating on (AU:4DX) stock is a Buy with a A$1.05 price target. To see the full list of analyst forecasts on 4DMedical Ltd stock, see the AU:4DX Stock Forecast page.
4DMedical Limited announced an update to its Top 20 Option Holders list and Distribution Schedule, correcting an error related to the expiry date of its Piggyback Options, now set to expire on 1 September 2027. This update ensures accurate information for stakeholders and maintains transparency in the company’s option holdings, which is crucial for investor confidence and market operations.
The most recent analyst rating on (AU:4DX) stock is a Buy with a A$1.05 price target. To see the full list of analyst forecasts on 4DMedical Ltd stock, see the AU:4DX Stock Forecast page.
4DMedical Limited has announced a collaboration with AstraZeneca in Brazil and a new contract with Spectrum Medical Imaging, marking its first involvement in Australia’s National Lung Cancer Screening Program. While the Spectrum contract is not immediately significant in terms of revenue, it is expected to grow over time, highlighting 4DMedical’s strategic expansion and potential impact on lung health management.
The most recent analyst rating on (AU:4DX) stock is a Buy with a A$1.05 price target. To see the full list of analyst forecasts on 4DMedical Ltd stock, see the AU:4DX Stock Forecast page.
4DMedical Ltd has released its Top 20 Investors Report, detailing the major stakeholders in the company as of September 11, 2025. The report highlights Citicorp Nominees Pty Limited as the largest investor, holding 24.41% of the issued capital. This information provides insight into the company’s shareholder structure, which is crucial for understanding its market positioning and potential influence on strategic decisions.
The most recent analyst rating on (AU:4DX) stock is a Buy with a A$1.05 price target. To see the full list of analyst forecasts on 4DMedical Ltd stock, see the AU:4DX Stock Forecast page.
4DMedical Ltd has announced the application for the quotation of its unlisted Piggyback options under the ASX Listing Rule 2.5, condition 6. This move involves the issuance of 23,470,090 options set to expire on September 1, 2027, reflecting the company’s strategic efforts to enhance its financial instruments and market presence.
The most recent analyst rating on (AU:4DX) stock is a Buy with a A$1.05 price target. To see the full list of analyst forecasts on 4DMedical Ltd stock, see the AU:4DX Stock Forecast page.
4DMedical Ltd announced the issuance of 7,179,233 unquoted equity securities, specifically options expiring on February 29, 2028, with an exercise price of $0.75. This move is part of the company’s strategic financial operations, potentially impacting its market positioning by enhancing its capital structure and providing opportunities for future growth and investment.
The most recent analyst rating on (AU:4DX) stock is a Buy with a A$1.05 price target. To see the full list of analyst forecasts on 4DMedical Ltd stock, see the AU:4DX Stock Forecast page.
4DMedical Ltd announced the quotation of 7,179,233 fully paid ordinary securities on the Australian Securities Exchange (ASX). This move is part of the company’s strategy to enhance its market presence and potentially increase its capital base, which could have implications for its operational expansion and stakeholder interests.
The most recent analyst rating on (AU:4DX) stock is a Buy with a A$1.05 price target. To see the full list of analyst forecasts on 4DMedical Ltd stock, see the AU:4DX Stock Forecast page.
4DMedical Limited has issued 339,255 fully paid ordinary shares following the exercise of options under its Long Term Incentive Plan. This issuance was completed without disclosure to investors under specific provisions of the Corporations Act, and the company has ensured compliance with relevant legislative requirements, indicating a strategic move to strengthen its financial position and incentivize long-term growth.
The most recent analyst rating on (AU:4DX) stock is a Buy with a A$1.05 price target. To see the full list of analyst forecasts on 4DMedical Ltd stock, see the AU:4DX Stock Forecast page.
4DMedical Ltd has announced the quotation of additional securities on the Australian Securities Exchange (ASX), with a total of 349,255 ordinary fully paid shares being issued. This move is part of the company’s ongoing efforts to enhance its capital structure and support its growth initiatives, potentially impacting its market positioning and providing opportunities for stakeholders.
The most recent analyst rating on (AU:4DX) stock is a Buy with a A$1.05 price target. To see the full list of analyst forecasts on 4DMedical Ltd stock, see the AU:4DX Stock Forecast page.
4DMedical Ltd has announced the issuance of unquoted equity securities, which includes performance rights and options under an employee incentive scheme. This move is part of the company’s strategy to incentivize its workforce and align their interests with the company’s growth objectives, potentially impacting its operational dynamics and market positioning.
The most recent analyst rating on (AU:4DX) stock is a Buy with a A$1.05 price target. To see the full list of analyst forecasts on 4DMedical Ltd stock, see the AU:4DX Stock Forecast page.
4DMedical Ltd announced the issuance of 12,964,580 unquoted equity securities, specifically options expiring on February 29, 2028, with an exercise price of $0.75. This move is likely to impact the company’s financial structure and could influence its market positioning by potentially increasing capital for future projects, affecting stakeholders’ interests.
The most recent analyst rating on (AU:4DX) stock is a Buy with a A$1.05 price target. To see the full list of analyst forecasts on 4DMedical Ltd stock, see the AU:4DX Stock Forecast page.
4DMedical Limited has announced agreements with a leading global pharmaceutical company, Royal Melbourne Hospital, and Spectrum Medical Imaging to deploy its lung health analysis software. These agreements, effective until 2027, aim to enhance lung cancer screening and lung health assessments in Brazil and Australia, including support for the National Lung Cancer Screening Program. The collaboration with Spectrum Medical Imaging will integrate 4DMedical’s advanced analytical tools into existing imaging infrastructure, enhancing the quality and depth of lung health diagnostics.
The most recent analyst rating on (AU:4DX) stock is a Buy with a A$1.05 price target. To see the full list of analyst forecasts on 4DMedical Ltd stock, see the AU:4DX Stock Forecast page.
4DMedical Ltd announced the issuance of 3,270,165 unquoted securities, specifically options expiring on February 29, 2028, with an exercise price of $0.75. This move is part of the company’s strategic financial operations, potentially impacting its market positioning and offering new opportunities for stakeholders.
The most recent analyst rating on (AU:4DX) stock is a Buy with a A$1.05 price target. To see the full list of analyst forecasts on 4DMedical Ltd stock, see the AU:4DX Stock Forecast page.
4DMedical Ltd has announced the issuance of 3,270,165 fully paid ordinary securities, which will be quoted on the Australian Securities Exchange (ASX) under the code 4DX. This move is part of the company’s strategy to leverage convertible securities, potentially enhancing its financial flexibility and market positioning.
The most recent analyst rating on (AU:4DX) stock is a Buy with a A$1.05 price target. To see the full list of analyst forecasts on 4DMedical Ltd stock, see the AU:4DX Stock Forecast page.
4DMedical Limited has announced its upcoming Annual General Meeting (AGM) scheduled for 30 October 2025, where an election of directors will take place. The company is inviting nominations for director positions, with a deadline of 11 September 2025. This AGM is a significant event for 4DMedical as it continues to solidify its leadership and strategic direction in the medical imaging industry. The meeting will provide an opportunity for stakeholders to engage with the company’s ongoing advancements and future plans, reinforcing its commitment to revolutionizing respiratory care.
The most recent analyst rating on (AU:4DX) stock is a Buy with a A$1.05 price target. To see the full list of analyst forecasts on 4DMedical Ltd stock, see the AU:4DX Stock Forecast page.
4DMedical Limited announced the expiry of its listed options, exercisable at $0.55, with the official quotation ceasing on 25 September 2025. The company has provided instructions for holders to exercise their options before the expiry date, impacting stakeholders by potentially influencing the company’s financial strategy and market positioning.
The most recent analyst rating on (AU:4DX) stock is a Buy with a A$1.05 price target. To see the full list of analyst forecasts on 4DMedical Ltd stock, see the AU:4DX Stock Forecast page.
4DMedical Limited has received confirmation from the U.S. Centers for Medicare & Medicaid Services (CMS) for reimbursement of its CT:VQ™ software, marking a significant step towards broad market adoption. This reimbursement, set at $650.50 per scan, allows hospitals and imaging centers to integrate the technology into their workflows without additional capital investment, enhancing accessibility and economic viability. The technology offers comprehensive lung function assessments without radioactive exposure, improving patient care and expanding diagnostic capabilities to facilities lacking nuclear medicine resources. With both FDA approval and Medicare reimbursement, 4DMedical is poised to accelerate commercial integration across the U.S., engaging with leading hospital groups and academic institutions.
The most recent analyst rating on (AU:4DX) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on 4DMedical Ltd stock, see the AU:4DX Stock Forecast page.
4DMedical Limited has received $6.0 million in R&D Tax Incentive credits, bolstering its financial position alongside a $10.0 million strategic investment from Pro Medicus. This positions the company to advance the commercialization of its CT:VQ™ technology and other products. Additionally, a study published in a leading respiratory journal highlights the efficacy of 4DMedical’s XV LVAS® technology in predicting complications in COPD treatment, potentially improving patient outcomes and reducing healthcare burdens.
The most recent analyst rating on (AU:4DX) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on 4DMedical Ltd stock, see the AU:4DX Stock Forecast page.
4DMedical Limited has received FDA clearance for its CT:VQ™ product, marking a significant advancement in respiratory diagnostics. CT:VQ™ is the first non-contrast, CT-based ventilation-perfusion imaging technology, offering a substantial improvement over traditional nuclear VQ scans by eliminating the need for radiotracers and integrating seamlessly with existing CT infrastructure. This innovation not only simplifies the imaging process but also expands access to advanced diagnostic capabilities across the U.S. healthcare system. The company anticipates capturing a significant portion of the $1.1 billion U.S. market and expects CT:VQ™ to drive long-term growth in demand for ventilation-perfusion scans, potentially displacing traditional nuclear VQ scans entirely.
The most recent analyst rating on (AU:4DX) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on 4DMedical Ltd stock, see the AU:4DX Stock Forecast page.
4DMedical Limited announced its FY2025 full-year results, highlighting a 56% increase in operating revenue and a 95% rise in SaaS revenue compared to FY2024. The company secured a $10 million strategic investment from Pro Medicus and signed a reseller agreement with Philips, enhancing its market reach. The FDA submission for its CT:VQ™ software, a non-contrast lung imaging tool, is progressing well, potentially opening a $1.1 billion market opportunity in the U.S. The company is expanding its U.S. presence with new contracts and renewals at key healthcare sites, while its global SaaS product delivery has grown significantly, now serving 388 sites.
The most recent analyst rating on (AU:4DX) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on 4DMedical Ltd stock, see the AU:4DX Stock Forecast page.
4DMedical Ltd reported a significant increase in its operating revenue for FY2025, reaching $5.9 million, a 56% rise from the previous year. This growth was primarily driven by its SaaS offerings, which contributed $5.7 million. Despite the increase in revenue, the company still reported a net loss of $30.1 million, although this was an improvement from the previous year. The company also noted a substantial gain from the remeasurement of contingent consideration liability due to its acquisition of Imbio. Operating expenses slightly increased due to higher investment in commercialization, which was partially offset by reduced consultancy and travel costs.
The most recent analyst rating on (AU:4DX) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on 4DMedical Ltd stock, see the AU:4DX Stock Forecast page.
4DMedical Ltd announced the issuance of 56,112 unquoted equity securities, specifically options expiring on February 29, 2028. This move is part of the company’s strategic financial maneuvers, potentially impacting its market position and offering stakeholders insights into its future growth and operational plans.
The most recent analyst rating on (AU:4DX) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on 4DMedical Ltd stock, see the AU:4DX Stock Forecast page.
4DMedical Ltd has announced the quotation of 56,112 ordinary fully paid securities on the ASX, effective from August 26, 2025. This move reflects the company’s ongoing efforts to enhance its market presence and operational capabilities, potentially impacting its industry positioning and offering new opportunities for stakeholders.
The most recent analyst rating on (AU:4DX) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on 4DMedical Ltd stock, see the AU:4DX Stock Forecast page.
4DMedical Limited has secured a $10 million strategic investment from Pro Medicus, a leader in medical imaging software. This investment will help 4DMedical accelerate its commercial pipeline and advance its CT:VQ™ product towards regulatory clearance in the U.S. The investment is structured as a hybrid debt and equity loan, aligning the interests of both companies’ shareholders. This strategic move is expected to strengthen 4DMedical’s market position and enhance its growth prospects, particularly with the anticipated FDA clearance of CT:VQ™ and the company’s expanding partnerships and operational growth.
The most recent analyst rating on (AU:4DX) stock is a Buy with a A$0.70 price target. To see the full list of analyst forecasts on 4DMedical Ltd stock, see the AU:4DX Stock Forecast page.
4DMedical Ltd has announced a proposed issue of 40 million fully paid ordinary securities, set to be issued on August 2, 2027. This strategic move is expected to bolster the company’s financial position, potentially enhancing its market presence and providing additional resources to further develop its cutting-edge medical imaging technologies.
The most recent analyst rating on (AU:4DX) stock is a Buy with a A$0.70 price target. To see the full list of analyst forecasts on 4DMedical Ltd stock, see the AU:4DX Stock Forecast page.
4DMedical Limited reported a significant increase in its financial performance for FY25, with operating revenue rising by 56% and SaaS revenue by 95% compared to FY24. The company secured a $10 million strategic investment from Pro Medicus, which will accelerate its commercial pipeline and support the advancement of its CT:VQ™ technology towards regulatory clearance in the U.S. This investment will also aid in expanding production capabilities and enhancing global deployment of its imaging technologies, thereby strengthening 4DMedical’s market position and offering substantial growth opportunities.
The most recent analyst rating on (AU:4DX) stock is a Buy with a A$0.70 price target. To see the full list of analyst forecasts on 4DMedical Ltd stock, see the AU:4DX Stock Forecast page.